Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...

Report commissioned by govt analysed cost-effectiveness of 2 medicines, comparing them to to chemo in patients with newly ...

An expert explained the importance of the FDA’s approval of Ensacove for patients with ALK-positive non-small cell lung cancer. Ensacove (ensartinib) has been approved by the Food and Drug ...

Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ...

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

An application was submitted to the European Medicines Agency seeking approval for treatment with sugemalimab in stage 3 ...

Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication. Alecensa ...

and has shown anti-tumor effects in mice with intracranial tumors driven by TRKA and ALK. The recommended ROZLYTREK dosage for ROS1-positive NSCLC is 600 mg once daily, with or without food ...

Olverembatinib (HQP1351), a novel, next-generation TKI and the first third-generation BCR-ABL1 TKI, has been approved in ...

Teacher Retirement System of Texas lifted its stake in shares of Nuvalent, Inc. (NASDAQ:NUVL – Free Report) by 43.1% during the fourth quarter, according to its most recent disclosure with the ...